Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam scraps RNAi drug development over safety concerns
ATTR amyloidosis disease occurs due to the deposition of transthyretin in peripheral tissues. The company said study safety monitors recommended that the phase 3 trial be stopped after
ATTR amyloidosis disease occurs due to the deposition of transthyretin in peripheral tissues. The company said study safety monitors recommended that the phase 3 trial be stopped after
Teva said the divestment of the assets and operations was part of an undertaking that it made to the European Commission related to the acquisition of Actavis Generics
Brilinta was being tested against clopidogrel in 13,885 patients in 28 countries. The study, dubbed Euclid, is the largest trial of its kind in such patients and forms
GCA is a chronic, potentially life-threatening autoimmune condition caused by inflammation of large and medium-sized arteries, most often in the head, but also in the aorta and its
Ohsumi used baker's yeast to find how cells recycle their content, a process known as autophagy, a Greek term for self-eating. The official website of the Nobel Prize
The drug, MEDI2070, is currently being tested in mid-stage clinical trials for patients with moderate-to-severe Crohn’s disease and ulcerative colitis. The licensing agreement will include an initial payment
The pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) is for patients with chronic hepatitis C virus (HCV) genotype 1 who failed treatment with DAAs, including therapy with an
The company, which has a global workforce of 42,300 in 75 countries, said around 500 of the job cuts would be in Denmark. Majority of job cuts will
Arrowhead will get $35m up front and will be eligible to receive up to $617m in milestone payments. Amgen will also invest $21.5m in Arrowhead common stock. royalties
It was the second late-stage study for ITI-007. In an earlier phase 3 study, the drug was tested against a placebo, and the higher of two doses succeeded.